NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2025, along with recent ...
Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...
First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...
United Therapeutics Corporation today announced the first clinical xenotransplantation in its EXPAND study of the UKidneytm in patients with end-stage renal disease (ESRD). The successful transplant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback